Update on hepatitis C: Direct-acting antivirals. World journal of hepatology Seifert, L. L., Perumpail, R. B., Ahmed, A. 2015; 7 (28): 2829-2833


Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.

View details for DOI 10.4254/wjh.v7.i28.2829

View details for PubMedID 26668694